Contents

ORIGINAL ARTICLE
Retrospective Study
204  Association of trainee participation with adenoma and polyp detection rates
Qayed E, Shea L, Goebel S, Bostick RM

211  Nerve preserving vs standard laparoscopic sacropexy: Postoperative bowel function
Cosma S, Petruzzelli P, Danese S, Benedetto C

Observational Study
220  Adult intussusception: A case series and review
Shenoy S

META-ANALYSIS
228  Does music reduce anxiety and discomfort during flexible sigmoidoscopy? A systematic review and meta-analysis
Shanmuganandan AP, Siddiqui MRS, Farkas N, Sran K, Thomas R, Mohamed S, Swift RI, Abulafi AM

CASE REPORT
238  Successful endoscopic treatment of an intraductal papillary neoplasm of the bile duct
Natov NS, Horton LC, Hegde SR
World Journal of Gastrointestinal Endoscopy
Volume 9  Number 5  May 16, 2017

About Cover

Editorial Board Member of World Journal of Gastrointestinal Endoscopy, AMarcelo Campos Silva, MSc, Academic Research, Medical Assistant, Department of Gastroenterology and Endoscopy, Hospital Mae de Deus, Porto Alegre, RS 90430-091, Brazil

Aim and Scope

World Journal of Gastrointestinal Endoscopy (World J Gastroint Endosc, WJGE, online ISSN 1948-5190, DOI: 10.4253) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJGE covers topics concerning gastroscopy, intestinal endoscopy, colonoscopy, capsule endoscopy, laparoscopy, interventional diagnosis and therapy, as well as advances in technology. Emphasis is placed on the clinical practice of treating gastrointestinal diseases with or under endoscopy.

We encourage authors to submit their manuscripts to WJGE. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

Indexing/Abstracting

World Journal of Gastrointestinal Endoscopy is now indexed in Emerging Sources Citation Index (Web of Science), PubMed, and PubMed Central.

Flyleaf

I-III

Editorial Board

Editors for

This Issue

NAME OF JOURNAL
World Journal of Gastrointestinal Endoscopy
ISSN
ISSN 1948-5190 (online)
LAUNCH DATE
October 15, 2009
FREQUENCY
Monthly
EDITORS-IN-CHIEF
Atsushi Imagawa, PhD, Director, Department of Gastroenterology, Mitoyo General Hospital, Kani-oka, Kagawa 769-1695, Japan
Juan Manuel Herrera Gutierrez, PhD, Academic Fellow, Chief Doctor, Professor, Unidad de Gestión Clínica de Aparato Digestivo, Hospital Universitario Virgen Macarena, Sevilla 41009, Sevilla, Spain
EDUCATIONAL BOARD MEMBERS
All editorial board members resources online at http://www.wjgnet.com/1948-5190/editorialboard.htm

EDITORIAL OFFICE
Xiu-Xia Song, Director
World Journal of Gastrointestinal Endoscopy
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com

Editorial Board Member of World Journal of Gastrointestinal Endoscopy, AMarcelo Campos Silva, MSc, Academic Research, Medical Assistant, Department of Gastroenterology and Endoscopy, Hospital Mae de Deus, Porto Alegre, RS 90430-091, Brazil

Responsible Assistant Editor: Xiang Li
Responsible Science Editor: Jin-Xin Kong
Responsible Electronic Editor: Huan-Liang Wu
Proofing Editor-in-Chief: Lian-Sheng Ma

Proofing Editorial Office Director: Xiu-Xia Song

Publication Date
May 16, 2017

Copyright
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

Special Statement
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

Instructions to Authors
http://www.wjgnet.com/bpg/geminfo/204

Online Submission
http://www.f6publishing.com

WJGE | www.wjgnet.com

II
May 16, 2017 | Volume 9 | Issue 5
Successful endoscopic treatment of an intraductal papillary neoplasm of the bile duct

Nikola S Natov, Laura C Horton, Sanjay R Hegde

Abstract

We present a case of a 76-year-old man with right upper quadrant abdominal pain and weight loss, who was found to have an intraductal papillary neoplasm of the bile duct (IPNB) of the pancreaticobiliary subtype, deemed curatively resectable. The patient declined surgery and opted for endoscopic therapy. He underwent two sessions of endoscopic retrograde cholangiopancreatography-guided radiofrequency ablation (ERCP-g-RFA). Ten months later, no evidence of recurrence was identified on repeat ERCP. To our knowledge, this is the first reported case of successful use of RFA as a primary treatment modality for resectable IPNB.

Key words: Bile duct neoplasms; Ablation technique; Common bile duct diseases; Extrahepatic bile duct; Advanced endoscopy

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Intraductal neoplasms of the bile duct (IPNB) classically present with jaundice and/or pruritus, but nonspecific symptoms such as right upper quadrant discomfort and weight loss may also develop. The first-line treatment for these tumors is surgical resection. Endoscopic retrograde cholangiopancreatography-guided radiofrequency ablation (RFA) has historically been used as adjunctive treatment; self-expanding metal stents may be used for palliation. We report a case of successful primary treatment of an IPNB with RFA alone.
INTRODUCTION

Intraductal papillary neoplasms of the bile duct were first recognized as a distinct entity by the World Health Organization in 2010[1]. These tumors may harbor varying degrees of dysplasia and even invasive malignancy[1,2]. Surgical resection is therefore recommended in patients who are operative candidates[1]. Non-surgical cases are managed with palliative biliary stenting using self-expandable metal stents (SEMSs), and radiofrequency ablation (RFA) has been employed as an adjunctive therapy for malignant biliary obstruction of several different etiologies[3-6]. RFA is safe, produces good 90-d stent luminal patency rates, and has been associated with an improvement in clinical outcomes[5,7,8]. However, its utility as a primary treatment modality has not been studied.

CASE REPORT

A 76-year-old man with a history of coronary artery disease and tobacco abuse was referred to our institution for evaluation of a common bile duct (CBD) stricture. Several months prior, he had presented to his primary care physician with right upper quadrant abdominal pain associated with an unintentional weight loss of 13 kg. Liver function tests (LFTs) revealed an AST of 46 IU/L (10-42), ALT of 37 IU/L (0-54), ALP of 197 IU/L (40-130), and a TB of 0.4 mg/dL (0.2-1.1). Mild intrahepatic ductal dilatation and a CBD of 10 mm were seen on right upper quadrant ultrasound. There was no choledocholithiasis. Subsequent magnetic resonance cholangiopancreatography revealed intra- and extrahepatic biliary ductal dilatation and a filling defect in the distal CBD. The pancreatic duct was not dilated. The patient was referred for endoscopic retrograde cholangiopancreatography (ERCP) at a different facility. Inspection of the ampulla of Vater was normal. The CBD was cannulated using a 0.35 inch sphincterotome and guidewire, and initial contrast injection showed dilatation of the CBD to approximately 15 mm and a saccular collection of contrast distally. A 10 mm biliary sphincterotomy was performed, and no choledocholithiasis or sludge was found after sweeping of the CBD. The procedure was aborted due to hypotension and hypoxemia before biopsies could be obtained.

The patient was brought back for repeat ERCP six weeks later. Following removal of the plastic stent and balloon sphincteroplasty to 10 mm, the CBD was cannulated using a pediatric gastroscope to allow for direct visualization of the intraductal mucosa. Catheter-based cholangioscopy was not available at the outside hospital. The area of the stricture appeared nodular and erythematous. The procedure was aborted due to hypotension and hypoxemia before biopsies could be obtained.

The patient was then transferred to our institution for ERCP with SpyGlass™ cholangioscopy (Boston Scientific, Natick, MA). Initial cholangiogram confirmed a distal CBD stricture (Figure 1). A 10 mm polypoid lesion was seen with SpyGlass™ cholangioscopy (Figure 2), and targeted intraductal biopsies were performed using SpyBite™ forceps (Boston Scientific, Natick, MA). Pathological findings of atypical cells, papillary configuration, and bile duct epithelium with mucinous metaplasia were consistent with intraductal papillary neoplasm of the bile duct (IPNB) without malignant transformation (Figure 3). Immunohistochemical staining was positive for MUC1 and negative for CDX2, highlighting pancreaticobiliary and lack of intestinal epithelium, respectively. The normal appearance of the ampulla, intraductal location of the neoplasm, and histology excluded an ampullary lesion. Furthermore, the most distal aspect of the CBD was normal. He was referred to hepatobiliary surgery.
for consideration of pancreaticoduodenectomy with curative intent, but surgical intervention was deferred due to patient preference. The decision was made to proceed with ERCP-guided RFA as primary therapy. Two sessions of RFA using an 8 Fr Habib™ EndoHPB probe were performed at 10 W for 90 s (EMcision, Montreal, Canada). A 10 mm × 4 cm WallFlex™ fully covered SEMS was deployed following the first round of RFA and exchanged at the completion of the second RFA session, three months later (Boston Scientific, Natick, MA). The procedures were uncomplicated. Four months after the second RFA session, ERCP with SpyGlass™ was repeated, the biliary stent was removed, and no residual polypoid tissue or stricture was observed on occlusion cholangiogram (Figure 4) or with Spyglass™ choledochoscopy (Figure 5). The stent was not replaced. Cytology of distal CBD brushings revealed no malignant cells. Repeat ERCP six months later (nine months after the last RFA session) demonstrated a 10 mm distal CBD stricture but no mass lesion (Figure 6). Spyglass™ choledochoscopy revealed only erythematous mucosa in the distal CBD; targeted intraductal biopsies of this area were performed using SpyBite™ forceps and revealed reactive epithelium. Cytology was negative for malignant cells, and fluorescence in situ hybridization (FISH) analysis of the distal CBD brushings showed no abnormalities. The patient underwent his last ERCP six months later, and no residual stricture or CBD lesion was seen on cholangiogram. He remained asymptomatic, and his LFTs and weight normalized.

**DISCUSSION**

In 2010, the World Health Organization first categorized rare bile duct tumors characterized by papillary growth as intraductal papillary neoplasms of the bile duct\(^1\). IPNBs are associated with mucobilia due to excessive mucin secretion, and are more commonly found in the hepatic biliary system\(^1\). However, mucobilia may be absent, and extrahepatic growth patterns have been described\(^1,9\). Four histological subtypes exist including pancreaticobiliary, oncocytic, gastric, and intestinal\(^10,11\). Differentiation between subtypes is made according to morphology seen on hematoxylin and eosin staining and immunohistochemical features of mucin glycoproteins\(^10\). Pancreaticobiliary IPNB is more frequently associated with an invasive phenotype and harbors a worse prognosis\(^10,11\). IPNB tumors are graded based on degree of dysplasia, from low- to high-grade and finally to invasive carcinoma, which was seen in 74% of IPNBs in one study\(^1,2\). Pancreatic IPMNs are...
classified similarly and are thought to follow the same sequence from benign to malignant[2]. The incidence of IPNBs is highest in Far Eastern countries, and particularly in patients between 50 and 70 years of age, with a slight male predominance[1]. Patients may be asymptomatic, or may present with abdominal pain, jaundice, elevated LFTs, or cholangitis[2,3]. Biliary ductal dilatation and an intraductal mass may be seen on computed tomography or magnetic resonance imaging[1]. Duodenoscopy may reveal a prominent ampulla with mucin secretion[1]. Diagnosis is often difficult; sensitivity of brush cytology and fluoroscopically-guided biliary biopsies is low, and mixed pathologic findings may be present within a single lesion[3,4]. The majority of IPNBs contain high-grade epithelial neoplasia or carcinoma; low- or intermediate grade neoplasia is infrequent[3]. Excessive mucin secretion may impede identification of IPNB via cholangiography; cholangioscopy, however, can allow direct visualization of IPNBs[1]. Regardless of the level of dysplasia or presence of malignancy, treatment of IPNBs is warranted due to the heterogeneity of pathology within a single lesion, and to prevent complications such as obstructive jaundice and cholangitis[1]. Preoperative assessment of disease extent should be performed, and surgical resection is recommended for patients who are candidates without distant metastasis[1]. The surgical approach depends on tumor location, with pancreaticoduodenectomy being the procedure of choice for distal biliary lesions[1]. Palliative biliary stenting with SEMSs is employed in non-operative cases[2]. Over the last decade, much effort has been devoted to studying RFA as an adjunct therapy to stent placement. Using thermal energy, RFA induces coagulative necrosis of tumor tissue[13]. The procedure is safe and produces good 90-d stent luminal patency rates in patients with unresectable pancreatic carcinoma with obstructive jaundice[7,8]. RFA has also been used in the treatment of cholangiocarcinoma and biliary obstruction as a result of metastatic disease from distant primary malignancies[3-6]. These studies included only one patient with IPNB[4]. Use of RFA may result in benefits beyond local tumor ablation, and may induce secondary anti-tumor effects in patients with hepatocellular carcinoma and metastatic colorectal cancer[14]. RFA has also been associated with improved clinical outcomes, including prolonged survival[5,7]. The mechanism behind this positive effect on survival is not known but could be due to improved stent patency resulting in less infectious complications and superior biliary drainage which subsequently allows patients to receive oncologic treatment. Complications of RFA are rare but include biliary tract perforation, stricture formation, post-procedural pain, pancreatitis, cholecystitis, and bleeding[5,15]. Further investigation is needed to elucidate the effect of RFA on outcomes in patients with IPNB. This case demonstrates that, in patients who defer surgery, RFA, in combination with biliary stenting, may be used as a primary therapy for intraductal malignancies.

**REFERENCES**

1. Ohtsuka M, Shimizu H, Kato A, Yoshitomi H, Furukawa K, Tsuyuguchi T, Sakai Y, Yokosuka O, Miyazaki M. Intraductal papillary neoplasms of the bile duct. Int J Hepatol 2014; 2014: 459091 [PMID: 24949206 DOI: 10.1155/2014/459091]

2. Rocha FG, Lee H, Katabi N, DeMatteo RP, Fong Y, D’Angelica MI, Allen PJ, Klimstra DS, Jarnagin WR. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology 2012; 56: 1352-1360 [PMID: 22504729 DOI: 10.1002/hep.25786]

3. Tal AO, Vermehren J, Friedrich-Rust M, Bojunga J, Sarrazin C, Zeuzem S, Trojan J, Albert JG. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable...
malignant bile duct obstruction. World J Gastrointest Endosc 2014; 6: 13-19 [PMID: 24527176 DOI: 10.4253/wjge.v6.i1.13]

4 Figueroa-Barojas P, Bakhru MR, Habib NA, Ellen K, Millman J, Jamal-Kabani A, Gaidhane M, Kahaleh M. Safety and efficacy of radiofrequency ablation in the management of unresectable bile duct and pancreatic cancer: a novel palliation technique. J Oncol 2013; 2013: 910897 [PMID: 23690775 DOI: 10.1155/2013/910897]

5 Sharaiha RZ, Natov NS, Glockenberg KS, Widmer J, Gaidhane M, Kahaleh M. Comparison of metal stenting with radiofrequency ablation versus stenting alone for treating malignant biliary strictures: is there an added benefit? J Oncol 2013; 2013: 910897 [PMID: 23690775 DOI: 10.1155/2013/910897]

6 Dohler W, Schreiber F, Schwaighofer H, Gschwantler M, Plieschnegger W, Ziachehabi A, Mayer A, Kramer L, Kopecky A, Schrutka-Kölbl C, Wolkersdörfer G, Madl C, Berr F, Trauner M, Püspök A. Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. Surg Endosc 2014; 28: 854-860 [PMID: 24196547 DOI: 10.1007/s00464-013-3232-9]

7 Kallis Y, Phillips N, Steel A, Kaltsidis H, Vlavianos P, Habib N, Westaby D. Analysis of Endoscopic Radiofrequency Ablation of Biliary Malignant Strictures in Pancreatic Cancer Suggests Potential Survival Benefit. Dig Dis Sci 2015; 60: 3449-3455 [PMID: 26038094 DOI: 10.1007/s00464-013-3232-9]

8 Steel AW, Postgate AJ, Khorsandi S, Nicholls J, Jiao L, Vlavianos P, Habib N, Westaby D. Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointest Endosc 2011; 73: 149-153 [PMID: 21184881 DOI: 10.1016/j.gie.2010.09.031]

9 Kawaguchi Y, Kawashima Y, Maruno A, Ito H, Ogawa M, Izumi H, Furukawa D, Yazawa N, Nakagori T, Hirabayashi K, Mine T. An intraductal papillary neoplasm of the bile duct at the duodenal papilla. Case Rep Oncol 2014; 7: 417-421 [PMID: 25126070 DOI: 10.1159/000364999]

10 Kim KM, Lee JK, Shin JH, Lee KH, Lee KT, Sung JY, Jang KT, Heo JS, Choi SH, Choi DW, Lim JH. Clinicopathologic features of intraductal papillary neoplasm of the bile duct according to histologic subtype. Am J Gastroenterol 2012; 107: 118-125 [PMID: 21946282 DOI: 10.1038/ajg.2011.316]

11 Gordon-Weeks AN, Jones K, Harris E, Smith A, Silva M. Systematic Review and Meta-analysis of Current Experience in Treating IPNB: Clinical and Pathological Correlates. Ann Surg 2016; 263: 656-663 [PMID: 26501712 DOI: 10.1097/SLA.0000000000001426]

12 Narita M, Endo B, Mizunoto Y, Matsusue R, Hata H, Yamaguchi T, Otani T, Ikai I. Multicentric recurrence of intraductal papillary neoplasms of bile duct in the remnant intrahepatic bile duct after curative resection. Int J Surg Case Rep 2015; 12: 123-127 [PMID: 26070186 DOI: 10.1016/j.ijscr.2015.05.033]

13 Itokawa F, Takasawa A, Itokawa T, Maruyama S, Nakamura M, Watanabe Y, Moriyasu F, Kahaleh M, Habib N, Nagao T, Yokoyama T, Kasuya K, Kawakami H. Evaluation of effects of a novel endoscopically applied radiofrequency ablation biliary catheter using an ex-vivo pig liver. J Hepatobiliary Pancreat Sci 2012; 19: 543-547 [PMID: 22038500 DOI: 10.1007/s00534-011-0465-7]

14 Hansler J, Wissniowski TT, Schuppman D, Witte A, Bernatik T, Hahn EG, Strobel D. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radiofrequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 2006; 12: 3716-3721 [PMID: 16773688 DOI: 10.3748/WJG.v12.i23.3716]

15 Zhou C, Wei B, Guo K, Zhai R. Biliary tract perforation following percutaneous endobiliary radiofrequency ablation: A report of two cases. Oncol Lett 2016; 11: 3813-3816 [PMID: 27313699 DOI: 10.3892/ol.2016.4436]
